Table of Contents
PARSIPPANY, N.J. — Teva Pharmaceutical Industries announced the release of limited doses of the FDA-approved generic version of EpiPen (epinephrine injection, USP) Auto-Injector, 0.3 mg, in the U.S. Teva’s generic version of the EpiPen Jr (epinephrine injection, USP) Auto-Injector, 0.15 mg, and an additional supply of Teva’s generic version of the EpiPen (epinephrine injection, USP) Auto-Injector, 0.3 mg is expected in 2019. The publically-available Wholesale Acquisition Cost (WAC) for the product is $300.
Brendan O’Grady, executive vice president and head of North America commercial at Teva said, “We’re pleased to provide access to Epinephrine Injection (Auto-Injector) for patients who may experience life-threatening allergic emergencies and we’re fully dedicated toward ensuring additional supply in 2019.”
With over 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
